Logo BSU

Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на этот документ: https://elib.bsu.by/handle/123456789/341412
Полная запись метаданных
Поле DCЗначениеЯзык
dc.contributor.authorRozema, D.B.-
dc.contributor.authorBlokhin, A.V.-
dc.contributor.authorWakefield, D.H.-
dc.contributor.authorBenson, J.D.-
dc.contributor.authorCarlson, J.C.-
dc.contributor.authorKlein, J.J.-
dc.contributor.authorAlmeida, L.J.-
dc.contributor.authorNicholas, A.L.-
dc.contributor.authorHamilton, H.L.-
dc.contributor.authorChu, O.-
dc.contributor.authorHegge, J.O.-
dc.contributor.authorWong, S.C.-
dc.contributor.authorTrubetskoy, S.-
dc.contributor.authorHagen |, C.M.-
dc.contributor.authorKitas, E.-
dc.contributor.authorWolff |, L.A.-
dc.contributor.authorLewis, D.L.-
dc.date.accessioned2026-02-10T10:43:27Z-
dc.date.available2026-02-10T10:43:27Z-
dc.date.issued2015-
dc.identifier.citationJournal of Controlled Release.2015; Vol. 209: P. 57-66.ru
dc.identifier.urihttps://elib.bsu.by/handle/123456789/341412-
dc.description.abstractThe safe and efficacious delivery of membrane impermeable therapeutics requires cytoplasmic ccess without the toxicity of nonspecific cytoplasmic membrane lysis. We have developed a mechanism for control of cytoplasmic release which utilizes endogenous proteases as a trigger and results in functional delivery of small interfering RNA (siRNA). The delivery approach is based on reversible inhibition of membrane disruptive polymers with protease-sensitive substrates. Proteolytic hydrolysis upon endocytosis restores the membrane destabilizing activity of the polymers thereby allowing cytoplasmic access of the co-delivered siRNA. Protease-sensitive polymer masking reagents derived from polyethylene glycol (PEG), which inhibit membrane interactions, and N-acetylgalactosamine, which targets asialoglycoprotein receptors on hepatocytes, were synthesized and used to formulate masked polymer-siRNA delivery vehicles. The size, charge and stability of the vehicles enable functional delivery of siRNA after subcutaneous administration and, with modification of the targeting ligand, have the potential for extrahepatic targeting.ru
dc.language.isoenru
dc.publisherElsevier BVru
dc.rightsinfo:eu-repo/semantics/openAccessru
dc.subjectЭБ БГУ::ЕСТЕСТВЕННЫЕ И ТОЧНЫЕ НАУКИ::Химияru
dc.subjectЭБ БГУ::ТЕХНИЧЕСКИЕ И ПРИКЛАДНЫЕ НАУКИ. ОТРАСЛИ ЭКОНОМИКИ::Медицина и здравоохранениеru
dc.titleProtease-triggered siRNA delivery vehiclesru
dc.typearticleru
dc.rights.licenseCC BY 4.0ru
dc.identifier.DOI10.1016/j.jconrel.2015.04.012-
Располагается в коллекциях:Статьи химического факультета

Полный текст документа:
Файл Описание РазмерФормат 
Блохин1.pdf1,21 MBAdobe PDFОткрыть
Показать базовое описание документа Статистика Google Scholar



Все документы в Электронной библиотеке защищены авторским правом, все права сохранены.